

and early allowance of all pending claims in light of the following remarks is courteously requested.

Please amend the above-identified application as follows:

In the Specification:

- On page 10, line 20, change "form" to -- from --.
- On page 22, line 30, change "RVS" to -- RSV --.
- On page 22, line 31, change "vectors" to -- vector --.
- On page 24, line 9, change "include" to -- including --.
- On page 24, line 23, change "an" to -- any --.
- On page 32, line 7, change "theses" to -- these --.
- On page 34, line 9, change "to" to -- the --.
- On page 35, line 15, delete "was".

In the Claims:

1. (Amended) A recombinant adeno-associated virus vector, which comprises:

- a) at least a portion of the adeno-associated virus genome;
- b) at least one eukaryotic based *cis*-acting regulatory sequence; and
- c) at least one eukaryotic based nucleic acid sequence [responsible for encoding] that encodes a therapeutic protein [or biologically active fragment thereof],

said virus vector having the property of regulating cell specific expression of said nucleic acid sequence or nucleic acid sequences upon stable transduction of a target ^{primary} mammalian cell

7. (Amended) A recombinant adeno-associated virus vector of claim 4 wherein [at least one] said eukaryotic *cis*-acting regulatory sequence is chosen from the region located from about hypersensitive site I to about hypersensitive site VI, in association with the human globin gene cluster.

In Claim 8, line 4, please change the second occurrence of "IV" to -- VI --.